Regentis Biomaterials’ Gelrin C Targets $3B Knee Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) is advancing its Gelrin C hydrogel as a practical, off-the-shelf regenerative solution for knee cartilage damage, targeting the massive clinical and economic burden of knee osteoarthritis (OA). Gelrin C is a cell-free hydrogel administered in a single 10-minute procedure, designed to regenerate cartilage without the need for multiple surgeries or specialized lab processing required by cell-based therapies. With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, Regentis believes Gelrin C can fit seamlessly into existing surgical workflows and address cartilage defects before they progress to costly OA. The article highlights that the annual U.S. economic burden of knee OA ranges from $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000. As Regentis moves Gelrin C toward commercialization, its single-stage design and proprietary hydrogel technology could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent expensive degenerative disease.

To view the full article, visit https://ibn.fm/yPKU2

About Regentis Biomaterials Ltd.

Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology uses synchronized, degradable hydrogel implants to regenerate damaged tissue, including inflamed cartilage and bone. GelrinC(R) is the lead product, a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. It aims to address a market of 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement; (4) social media distribution; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team, IW is uniquely positioned to serve private and public companies wanting to reach investors, influencers, and the public.